NCT06395870View on ClinicalTrials.gov

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 9, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions
B-Cell Non-Hodgkin Lymphoma-RecurrentB-Cell Non-Hodgkin Lymphoma-Refractory
Interventions
BIOLOGICAL

LUCAR-G39D cells product

Prior to infusion of the LUCAR-G39D, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.

Trial Locations (2)

230000

RECRUITING

Oncology Department, The First Affiliated Hospital of USTC west district, Hefei

300060

RECRUITING

Tianjin Cancer Hospital, Tianjin

Sponsors
All Listed Sponsors
collaborator

Nanjing Legend Biotech Co.

INDUSTRY

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT06395870 - Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter